Related Experiment Video
Updated: Apr 4, 2026

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
Published on: March 29, 2024
Future of combination therapy with dabrafenib and trametinib in metastatic melanoma
Yasaman Zia1, Lawrence Chen2, Adil Daud3
1a 1 UCSF Helen Diller Comprehensive Cancer Center , 1600 Divisadero Street, Room B708, San Francisco, CA 94115, USA +1 20 24 89 19 86 ; +1 41 55 14 69 69 ; yaszia@gmail.com.
Introduction:
Combination therapy with BRAF and MEK inhibitors is a recommended treatment strategy for metastatic melanoma patients with BRAF(V600) mutations. This treatment provides significant response rates and little added toxicity, with relatively improved survival outcomes compared to RAF/MEK inhibitor monotherapy and chemotherapy.
Areas Covered:
This review covers the pharmacology, efficacy, and toxicity data derived from clinical studies of dabrafenib, trametinib , and the combination thereof. The major downfall of combiDT is the limited durability of response, which is largely due to acquired resistance in the MAPK pathway.
Expert Opinion:
Future directions of combiDT concentrate on further combinations with immunotherapy or other targeted inhibitors, referred to triple-agent therapy, which may be essential to improving durability of responses and overcoming resistance.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy
Mitogens and the Cell Cycle

